AtriCure, Inc. SEC Filings

Sven Wehrwein, a director of AtriCure, Inc. (ATRC), executed matched transactions on 08/22/2025. He exercised 5,000 non-qualified stock options with an exercise price of $19.95, acquiring 5,000 shares. He simultaneously sold 5,000 common shares at $37.00. After these transactions he beneficially owned 34,374 shares and held options covering 35,000 shares exercisable through 11/11/2026. The options were originally granted on November 11, 2016, and vest per the schedule disclosed in the filing.

AtriCure, Inc. (ATRC) Form 144 discloses a proposed sale of 5,000 common shares through Morgan Stanley Smith Barney, with an aggregate market value listed at $185,000 and an approximate sale date of 08/22/2025. The filer states total shares outstanding of 49,701,415. The 5,000 shares were acquired on 08/22/2025 by stock option exercise from the issuer and paid in cash. The filing also lists a recent sale by the same person: on 08/19/2025 Sven Wehrwein sold 5,000 shares for $180,000. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.

Sven Wehrwein, a director of AtriCure, Inc. (ATRC), reported multiple transactions on 08/19/2025. He acquired 5,000 shares of common stock at $19.95 and sold 5,000 shares at $36, leaving him with 34,374 shares of common stock beneficially owned after the transactions. On the same date he was reported as acquiring a non-qualified stock option covering 5,000 shares with an exercise price of $19.95, reflecting a post-transaction total of 40,000 options. The filing notes these options were originally granted on November 11, 2016 and vest 25% after one year with the remainder vesting monthly over the following three years. The Form 4 is signed by Mr. Wehrwein on 08/21/2025.

A person affiliated with AtriCure, Inc. (ATRC) intends to sell 5,000 shares of the company's common stock through Morgan Stanley Smith Barney LLC on the NASDAQ. The notice lists an approximate sale date of 08/19/2025 and an aggregate market value of $180,000 based on that sale. The shares were acquired on 08/19/2025 through a stock option exercise from the issuer and payment was made in cash. The filer reports no securities sold in the past three months for the account covered by this notice and includes the standard representation that the seller does not possess undisclosed material information about the issuer.

This Schedule 13G reports that Macquarie entities beneficially own 2,503,205 common shares of AtriCure, representing 5.06% of the outstanding class (CUSIP 04963C209). The statement is jointly filed by Macquarie Group Limited, Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust. Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust each report sole voting and sole dispositive power over the 2,503,205 shares, while Macquarie Group Limited reports no sole voting or dispositive power. The filing includes a certification that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Wellington Management filed a Schedule 13G reporting beneficial ownership of AtriCure, Inc. common stock on behalf of clients. The reporting group indicates 3,969,269 shares, representing 8.02% of the class. Across the reporting entities, shared voting power is reported as 2,342,505 votes and shared dispositive power as 3,969,269 shares, while one entity lists shared dispositive power of 3,377,947 and a cover-page percent of 6.8% under its entry.

The filing states these securities are owned of record by clients of Wellington's investment advisers and were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control. Reporting entities are identified as holding companies (HC) and investment advisers (IA) under the applicable rules.

Michael H. Carrel, who serves as President, CEO and a Director of AtriCure, reported a charitable gift of 10,000 shares of AtriCure common stock on 08/08/2025 with no consideration received. After the reported transaction he beneficially owned 697,377 shares directly. The filing also discloses that 9,310 shares are held by his children and 2,250 shares are held by his parents, which he disclaims except for a pecuniary interest. The disclosure is coded as a gift and reflects insider compliance with Section 16 reporting.

AtriCure, Inc. (ATRC) Form 4: Director Regina E. Groves sold 2,452 common shares on 08-06-2025 at a weighted-average price of $36.82, a transaction valued at roughly $90 k.

After the sale, Groves directly owns 33,715 shares. No derivative securities were involved and the filing does not cite a Rule 10b5-1 trading plan. There are no disclosures of additional insider transactions, compensation changes, or company events in this filing.

The reported sale reduced her direct position by about 6.8% (from 36,167 to 33,715 shares). While a single Form 4 offers limited context, investors often track insider activity as a sentiment gauge. This transaction is modest relative to AtriCure’s average daily volume and does not, by itself, indicate a change in corporate fundamentals.

On this Form 4, AtriCure (ATRC) Chief Scientific Officer Vinayak S. Doraiswamy reported an open-market sale of 2,500 common shares on 08/05/2025 at $36.58 per share, yielding roughly $91 K in proceeds. After the transaction, he directly owns 71,872 shares, down about 3.4% from 74,372, leaving a stake worth ~$2.6 M at the sale price. No derivative trades were disclosed, and the filing cites no Rule 10b5-1 plan. Aside from this single sale, the document contains no financial results, guidance, or additional corporate events.